Home / Market News / $CLGN
benzinga Corporate Catalyst Impact 95/100 ● negative

CollPlant Biotechnologies Q2 Adj. EPS $(1.69) Misses $(0.24) Estimate, Sales $108.000K Miss $1.466M Estimate

Sep 30, 2026, 9:33 PM UTC · Primary ticker $CLGN

CollPlant Biotechnologies reported significantly wider-than-expected losses and substantially lower sales for Q2, missing analyst estimates by a large margin. This substantial underperformance in both profitability and revenue is a strong negative signal for the company's financial health and growth prospects.

CollPlant Biotechnologies (CLGN) reported a Q2 adjusted EPS of $(1.69), missing the analyst consensus of $(0.24) by over 600%. Concurrently, sales came in at $108,000, falling short of the $1.466 million estimate by over 92%. This dual miss indicates a severe underperformance against market expectations, suggesting potential operational challenges or weaker-than-anticipated market demand for their products. This news is highly negative for CLGN, likely leading to a significant short-term price decline as investors react to the poor financial results. Long-term implications depend on the company's ability to address these issues and improve future performance, but the immediate outlook is bearish.

$CLGN negative Significant earnings and sales miss
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.